|
DNAPrint Genomics, Inc. is a pharmaceutical company that has developed a novel form of genetic testing to assist with the drug development process, but the technology has other, and to some more interesting applications in the area of genealogy. Through the measurement of an individual's genome, the company is able to infer detailed genetic or biogeographical ancestry with respect to the major continental and sub-continental populations that founded most of modern day human diversity . The technology can report ancestral heritage for a person contributed from their male or female line, or all ancestors together extending back in some cases many thousands of years.
DNAP's technology was originally developed to produce genomics-based products and services in two primary markets: biomedical and forensics. DNAP develops diagnostic tests and theranostic products (drug/test combinations) using ancestry-informed and drug response genetic marker studies combined with computational modeling technology. DNAP uses simulated pre-trials to design actual trials better and targets patients with genetic profiles indicating their propensity to have the best clinical responses. Similar to the benefit a genealogist derives from a detailed knowledge of detailed heritage written in their DNA, do drug developers also benefit from understanding details of a patients heritage because the likelihood to respond to a given medication is almost entirely based on genetics. DNAP's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease), and the company hopes to implement its new genome based tools to ensure that the drug passes through clinical trials efficiently, and after approval is used in target populations that are genetically compatible.
Trace Genetics, Inc. is a modern DNA-testing laboratory that provides genetic services to consumers, law enforcement and. Trace specializes in genetic identity DNA analysis with expertise in ancestry genealogy, forensics, molecular diagnostics and population genetics. Co-founders Ripan S. Malhi and Jason Eshleman have over a decade of DNA identification experience and are considered leaders in the industry. They are two of only a handful of researchers world-wide considered to be experts in ancient DNA analysis, and have worked with ancient human and non-human DNA from several hundred to several thousand years old. They were chosen to be part of the ground-breaking Kennewick Man research team for the Department of the Interior and have worked on numerous other projects analyzing both single specimens and ancient populations. Both Dr. Malhi and Dr. Eshleman completed their doctoral research at UC Davis, where they worked extensively with the gene genealogies of Native American Peoples.
Ellipsis Biotherapeutics, Inc. Ellipsis is a biotechnology company that provides single nucleotide polymorphism (SNP) genotyping to clients in the private, public and government sectors. Ellipsis together with academic collaborators has isolated novel genes that predispose people to development of Crohn's disease. Ellipsis was founded to commercialize the disease gene discovery efforts of its founders, primarily in the area of inflammatory disease. Since then, it has leveraged its expertise in SNP genotyping to provide high quality service to a variety of clients in academic, government and industrial research settings.
|
|
|
 |
|
